WASHINGTON–(BUSINESS WIRE)–#ML—CorVista Health, Inc, a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the election of Dr. Tim Attebery to its Board of Directors.
As the company approaches commercialization, CorVista Health recognizes the importance of enhancing its Board of Directors with specialized expertise in the field of cardiovascular care. Dr. Attebery’s significant contributions in reshaping the model of cardiovascular care delivery in the USA through his innovative leadership at organizations such as the American College of Cardiology and Cardiovascular Associates of America make him a highly valued addition to the board.
“Our shareholders, along with the leadership team of CorVista Health, are thrilled to have Tim join our Board of Directors,” said Don Crawford, President, and CEO of CorVista Health. “His insights and expertise will enrich our board, and I am confident that his vast experience in healthcare and leadership will be instrumental in driving our future growth and development.”
As a member of our board, Dr. Attebery will provide further guidance and governance, drawing from his deep understanding of the cardiovascular healthcare space. His involvement will additionally support CorVista Health as it enters the next phase of growth following FDA Breakthrough Designation for their pulmonary hypertension focused device.
“I believe CorVista Health can transform the way cardiovascular disease is diagnosed, particularly in underserved geographies and populations with the greatest need,” said Dr. Attebery. “Advancements in healthcare are essential to help improve the diagnosis of cardiovascular patients especially in rural areas, and CorVista’s innovative solution has the potential to make a tremendous impact to our healthcare system.”
About CorVista® Health
CorVista Health, Inc. is applying machine learning to develop a novel cardiac diagnostic platform, CorVista® System, with the aim of transforming cardiovascular care and the patient experience. For more information, visit corvista.com CorVista Health is dedicated to addressing the FDA’s call to action for leveraging health technologies to advance health equity, as presented by FDA Commissioner, Dr. Robert Califf. Particularly, the decline in life expectancy in rural areas has been cited as key evidence of disparate health outcomes. CorVista System has the potential to enable more equitable care by providing access to immediately actionable, high-quality cardiovascular status results in low-resource settings, where access to capital-intensive equipment and the qualified specialists needed to operate them may not be available. In this way, the CorVista System is uniquely positioned to advance the quality of care in rural and low-resource settings.
About CorVista® System
CorVista System is a non-invasive point-of-care solution that is intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise. Within minutes of the test, the CorVista® Analysis is available in a secure web portal to aid physicians in rapidly diagnosing and treating patients with suspected cardiovascular disease, answering important clinical questions to guide better treatment decisions. CorVista System is an investigational device limited by federal law to investigational use. CorVista System is not available for commercial distribution.
Contacts
Chris Bing Ernst
415.710.9445
cernst@corvista.com
